ImmusanT Secures $20,000,000 Series A Round

  • Feed Type
  • Date
  • Company Name
  • Mailing Address
    One Broadway 14th Floor Cambridge, MA 02142
  • Company Description
    ImmusanT is an early stage biotechnology company focused on developing a treatment, and a set of diagnostic and monitoring tools to manage patients with celiac disease.
  • Website
  • Transaction Type
    Venture Equity
  • Transaction Amount
  • Transaction Round
    Series A
  • Proceeds Purposes
    The proceeds will fund the Nexvax2 therapeutic and diagnostic development plan to the point of demonstrating proof-of-concept. ImmusanT expects to initiate the next clinical trial in early 2012.
  • M&A Terms
  • Venture Investor
    Vatera Healthcare Partners

Trending on Xconomy